Publication | Closed Access
Selective COX-2 inhibitor regulates the MAP kinase signaling pathway in human osteoarthritic chondrocytes after induction of nitric oxide
18
Citations
0
References
2005
Year
Nitric OxideLipid PeroxidationPathologyCell DeathOsteoporosisOrthopaedic SurgeryMusculoskeletal ResearchOxidative StressInflammationSelective Cox-2 InhibitorBone Morphogenic ProteinCartilage DegenerationOsteoarthritisInflammatory Rheumatic DiseaseCell SignalingRheumatoid ArthritisMitochondrial Membrane PotentialRheumatologyOxysterolBiochemistryMap KinaseReactive Oxygen SpeciePharmacologyCell BiologyAnti-inflammatoryMedicine
The purpose of this study was to examine the effect of cyclooxygenase-2 (COX-2) inhibitors on the mitogen-activated protein (MAP) kinase signaling pathway and synthesis of glucosaminoglycan after nitric oxide (NO) induction in articular human chondrocytes. After NO induction, the cells were divided into three groups that were treated with either ethanol (control); a selective COX-2 inhibitor (Celecoxib), or no additive, and evaluated. There were no differences in the effect of the selective COX-2 inhibitor on mitochondrial membrane potential or Annexin V levels. However, Celecoxib significantly decreased prostaglandin E2 (PGE2) production. Celecoxib also decreased the phosphorylation state of p38 and p44/42 of MAP kinase. The ratio of chondroitin-6 sulfate (C6S)/C4S was increased in response to the exposure to Celecoxib. Celecoxib did not affect apoptosis, but decreased the activation of MAP kinase in osteoarthritic chondrocytes after NO induction. NO-induced OA chondrocytes were associated with the p38 and the p44/42 MAPK signaling pathways, in a pathway that is distinct from PGE2-mediated apoptosis.